Parent Project Muscular Dystrophy: Education Matters

Parent Project Muscular Dystrophy: Education Matters: "Education Matters Guides
To better assist parents and teachers in providing a fulfilling education for the student with Duchenne, PPMD has created the following helpful guides:"

- A Parent's Guide

- A Teacher's Guide

- Adaptive PE

- Learning & Behavior in Duchenne

Make sure that your school has these.

Biglycan Treatment Shows Promise in Muscular Dystrophy Mouse Model

Biglycan Treatment Shows Promise in Muscular Dystrophy Mouse Model: "Biglycan Treatment Shows Promise in Muscular Dystrophy Mouse Model

Treatment with the protein biglycan reduces muscle damage in a mouse model of Duchenne and Becker muscular dystrophies (DBMD), according to new research supported, in part, by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). Dystrophin deficient (mdx) mice given systemic injections of purified biglycan were less susceptible to the loss of muscle strength that characterizes the disease. The study was reported in the Proceedings of the National Academy of Sciences"

Parent Project Muscular Dystrophy: Home

Parent Project Muscular Dystrophy: Home: "Dr. Brenda Wong and her colleagues at Cincinnati Children's Hospital Medical Center in Ohio are actively recruiting boys with Duchenne for their IGF-1 study: Safety and Efficacy Study of IGF-I in Duchenne."

Parent Project Muscular Dystrophy: Home

Parent Project Muscular Dystrophy: Home: "PPMD and DuchenneConnect are pleased to announce that the Clinic Services Resource is now available for patients and families of those affected by Duchenne and Becker muscular dystrophy. All those who receive care in the United States are encouraged to join this dynamic new expansion of the DuchenneConnect Registry."

AVI BioPharma Live Podcast 6/20/11

AVI BioPharma Live Podcast 6/20/11: "Chris Garabedian, CEO of AVI BioPharma, will participate in a live podcast hosted by PPMD on June 20, 2011 at 1:00 pm ET. Chris will review AVI’s development of eteplirsen, the company’s Phase 2 exon 51 skipping therapeutic candidate to restore dystrophin expression and treat DMD. Chris will also respond to questions submitted by email on or before June 16, 2011. Questions can be submitted by emailing info@parentprojectmd.org with the subject line: AVI Webinar. "